Kura Oncology (KUR) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Venetoclax, Daunorubicin, Azacitidine (Aza), ziftomenib, Ziftomenib, Cytarabine (Ara-C) | Acute Myeloid Leukemia (Aml) | Phase III | Recruiting | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | May 16, 2025 | ― |
| ziftomenib, Ziftomenib, Imatinib Mesylate | Gastrointestinal Stromal Tumor (Gist), Gastrointestinal Stromal Tumor (Gist) Of The Gastrointestinal Tract, Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors | Phase I | Recruiting | A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Oct 14, 2024 | ― |
| Cabozantinib, Adagrasib, Darlifarnib | Colorectal Cancer (Crc), Pancreatic Ductal Adenocarcinoma (Pdac), Non Small Cell Lung Cancer (Nsclc), Clear Cell Renal Cell Carcinoma (Ccrcc), Renal Cell Carcinoma (Kidney Cancer), Solid Tumors With Hras Alterations | Phase I | Recruiting | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Aug 17, 2023 | ― |
| Gilteritinib, Fludarabine, Cytarabine, Idarubicin, ziftomenib, Ziftomenib, Granulocyte Colony-Stimulating Factor | Acute Myeloid Leukemia, Leukemia, Myeloid, Acute, Neoplasms By Histologic Type, Leukemia, Leukemia, Myeloid, Hematologic Malignancy, Acute Leukemia, Aml, Aml With Mutated Npm1, Kmt2ar, Npm1 Mutation, Mll Rearrangement | Phase I | Recruiting | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Aug 07, 2023 | ― |
| Azacitidine, Cytarabine, Venetoclax, Quizartinib, Daunorubicin, ziftomenib, Ziftomenib | Acute Myeloid Leukemia, Refractory Aml, Acute Myeloid Leukemia, In Relapse, Aml With Mutated Npm1, Kmt2ar, Npm1 Mutation, Mixed Lineage Leukemia Gene Mutation, Acute Myeloid Leukemia Recurrent, Myeloid Sarcoma, Nucleophosmin 1-Mutated Acute Myeloid Leukemia | Phase I | Recruiting | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Feb 09, 2023 | ― |
| Alpelisib, Tipifarnib | Hnscc | phase1AndPhase2 | Active Not Recruiting | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Jul 27, 2021 | ― |
| Midazolam, Itraconazole, ziftomenib, Ziftomenib | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Malignant Neoplasm, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia Of Ambiguous Lineage, Mixed Phenotype Acute Leukemia | phase1AndPhase2 | Recruiting | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Jun 25, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Venetoclax, Daunorubicin, Azacitidine (Aza), ziftomenib, Ziftomenib, Cytarabine (Ara-C) | Phase III | Acute Myeloid Leukemia (Aml) | Recruiting | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | May 16, 2025 | ― |
| ziftomenib, Ziftomenib, Imatinib Mesylate | Phase I | Gastrointestinal Stromal Tumor (Gist), Gastrointestinal Stromal Tumor (Gist) Of The Gastrointestinal Tract, Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors | Recruiting | A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Oct 14, 2024 | ― |
| Cabozantinib, Adagrasib, Darlifarnib | Phase I | Colorectal Cancer (Crc), Pancreatic Ductal Adenocarcinoma (Pdac), Non Small Cell Lung Cancer (Nsclc), Clear Cell Renal Cell Carcinoma (Ccrcc), Renal Cell Carcinoma (Kidney Cancer), Solid Tumors With Hras Alterations | Recruiting | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Aug 17, 2023 | ― |
| Gilteritinib, Fludarabine, Cytarabine, Idarubicin, ziftomenib, Ziftomenib, Granulocyte Colony-Stimulating Factor | Phase I | Acute Myeloid Leukemia, Leukemia, Myeloid, Acute, Neoplasms By Histologic Type, Leukemia, Leukemia, Myeloid, Hematologic Malignancy, Acute Leukemia, Aml, Aml With Mutated Npm1, Kmt2ar, Npm1 Mutation, Mll Rearrangement | Recruiting | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Aug 07, 2023 | ― |
| Azacitidine, Cytarabine, Venetoclax, Quizartinib, Daunorubicin, ziftomenib, Ziftomenib | Phase I | Acute Myeloid Leukemia, Refractory Aml, Acute Myeloid Leukemia, In Relapse, Aml With Mutated Npm1, Kmt2ar, Npm1 Mutation, Mixed Lineage Leukemia Gene Mutation, Acute Myeloid Leukemia Recurrent, Myeloid Sarcoma, Nucleophosmin 1-Mutated Acute Myeloid Leukemia | Recruiting | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Feb 09, 2023 | ― |
| Alpelisib, Tipifarnib | phase1AndPhase2 | Hnscc | Active Not Recruiting | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Jul 27, 2021 | ― |
| Midazolam, Itraconazole, ziftomenib, Ziftomenib | phase1AndPhase2 | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Malignant Neoplasm, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia Of Ambiguous Lineage, Mixed Phenotype Acute Leukemia | Recruiting | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Jun 25, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Kura Oncology (DE:KUR) have in its pipeline
Kura Oncology DE:KUR is currently developing the following drugs: Venetoclax, Daunorubicin, Azacitidine (Aza), ziftomenib, Ziftomenib, Cytarabine (Ara-C), ziftomenib, Ziftomenib, Imatinib Mesylate, Cabozantinib, Adagrasib, Darlifarnib, Gilteritinib, Fludarabine, Cytarabine, Idarubicin, ziftomenib, Ziftomenib, Granulocyte Colony-Stimulating Factor, Azacitidine, Cytarabine, Venetoclax, Quizartinib, Daunorubicin, ziftomenib, Ziftomenib, Alpelisib, Tipifarnib, Midazolam, Itraconazole, ziftomenib, Ziftomenib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.